Apopharma

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

Phase 2

Completed

Conditions: Iron Overload Due to Repeated Red Blood Cell Transfusions

Interventions: Drug: Deferiprone DR tablets 1000 mg (Low dosage)
Drug: Deferiprone DR tablets 1000 mg (High dosage)

First Posted Date: 2019-01-14

Last Posted Date: 2021-07-16

Lead Sponsor: ApoPharma

Target Recruit Count: 30

Registration Number: NCT03802916

Locations: 🇬🇷
National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, Goudí, Athens, Greece
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States

and more 2 locations

Study of Parkinson's Early Stage With Deferiprone

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Deferiprone

First Posted Date: 2016-04-05

Last Posted Date: 2024-04-10

Lead Sponsor: ApoPharma

Target Recruit Count: 140

Registration Number: NCT02728843

Locations: 🇫🇷
CHU Charles Nicoll - Rouen, Rouen, France
🇬🇧
Newcastle Clinical Ageing Research Unit, Newcastle Upon Tyne, United Kingdom
🇩🇪
UKSH Campus Kiel, Neurologie, Kiel, Germany

and more 17 locations

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Deferiprone extended release
Drug: Deferiprone immediate release

First Posted Date: 2015-06-08

Last Posted Date: 2016-02-26

Lead Sponsor: ApoPharma

Target Recruit Count: 20

Registration Number: NCT02465489

Locations: 🇨🇦
Algorithme Pharma Inc., Mount-Royal, Quebec, Canada

Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects

Phase 1

Completed

Conditions: Asymptomatic HIV Infection

Interventions: Drug: Intravenous deferiprone
Drug: Placebo

First Posted Date: 2015-05-28

Last Posted Date: 2016-06-07

Lead Sponsor: ApoPharma

Target Recruit Count: 30

Registration Number: NCT02456558

Locations: 🇿🇦
VxPharma, Pretoria, South Africa
🇿🇦
Phoenix Pharma, Port Elizabeth, Eastern Cape, South Africa

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Phase 4

Terminated

Conditions: Iron Overload
Sickle Cell Disease
Other Anemias

Interventions: Drug: Deferiprone

First Posted Date: 2015-05-14

Last Posted Date: 2024-01-10

Lead Sponsor: ApoPharma

Target Recruit Count: 134

Registration Number: NCT02443545

Locations: 🇪🇬
Zagazig University, Alexandria, Egypt
🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇨🇦
Hospital for Sick Kids, Toronto, Ontario, Canada

and more 10 locations

Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Deferiprone oral solution
Drug: Deferiprone delayed release tablet formulation

First Posted Date: 2015-05-13

Last Posted Date: 2016-05-13

Lead Sponsor: ApoPharma

Target Recruit Count: 20

Registration Number: NCT02442310

Locations: 🇨🇦
Algorithme Pharma Inc., Mount-Royal, Quebec, Canada

Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects

Phase 1

Completed

Conditions: HIV Infection

Interventions: Drug: Deferiprone

First Posted Date: 2014-07-16

Last Posted Date: 2014-07-16

Lead Sponsor: ApoPharma

Target Recruit Count: 26

Registration Number: NCT02191657

Locations: 🇿🇦
PAREXEL International, Bloemfontein,, South Africa

Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Deferiprone sustained-release
Drug: Deferiprone immediate-release

First Posted Date: 2014-07-15

Last Posted Date: 2016-05-20

Lead Sponsor: ApoPharma

Target Recruit Count: 11

Registration Number: NCT02189941

Locations: 🇨🇦
Apotex Inc. BioClinical Development, Toronto, Ontario, Canada

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

Phase 3

Completed

Conditions: Pantothenate Kinase-Associated Neurodegeneration

Interventions: Drug: Deferiprone oral solution

First Posted Date: 2014-06-26

Last Posted Date: 2020-08-25

Lead Sponsor: ApoPharma

Target Recruit Count: 68

Registration Number: NCT02174848

Locations: 🇮🇹
Foundation Neurological Institute C. Besta, Milan, Italy
🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇩🇪
Klinikum der Universität München, Munich, Germany

and more 1 locations

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Phase 4

Terminated

Conditions: Iron Overload
Other Anemias
Sickle Cell Disease

Interventions: Drug: Deferiprone
Drug: Deferoxamine

First Posted Date: 2014-01-22

Last Posted Date: 2021-08-10

Lead Sponsor: ApoPharma

Target Recruit Count: 230

Registration Number: NCT02041299

Locations: 🇺🇸
Children's Hospital, New Orleans, Louisiana, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇪🇬
Ains Shams University, Cairo, Egypt

and more 30 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy